fbpx
 List – 30 Drug Patents that are Expiring in 2028

List – 30 Drug Patents that are Expiring in 2028

0

Mutamycin
Mitomycin

PatentsExpiration Date
US9539241January 2, 2028

Dosage: Intravenous Powder For Injection
Company: Biochem Pharmaceutical Industries
Ingredients: MITOMYCIN
Treatment: Upper Gastro-intestinal Cancers, Anal Cancers, and Breast Cancers

Farydak
Panobinostat

PatentsExpiration Date
US7989494January 17, 2028

Dosage: Oral
Company: Secura Bio
Ingredients: PANOBINOSTAT LACTATE
Treatment: Various Cancers

Sivextro
Tedizolid

PatentsExpiration Date
US8420676February 23, 2028
US7816379June 20, 2028
US9624250February 3, 2030
US9624250February 3, 2030
US8426389December 31, 2030

Dosage: Oral, Intravenous
Company: Cubist Pharmaceuticals
Ingredients: TEDIZOLID PHOSPHATE
Treatment: Complicated Skin And Skin-structure Infections (CSSSIS)

Xenleta
Lefamulin

PatentsExpiration Date
US8153689March 19, 2028
US8071643January 16, 2029
US9120727May 23, 2031

Dosage: Oral, Intravenous
Company: Nabriva Therapeutics
Ingredients: LEFAMULIN ACETATE
Treatment: Pneumonia

Vosevi
Sofosbuvir/Velpatasvir/Voxilaprevir

PatentsExpiration Date
US9585906March 21, 2028
US8735372September 21, 2028
US8889159September 26, 2029
US9868745November 16, 2032
US9296782July 17, 2034

Dosage: Oral
Company: Gilead Sciences
Ingredients: SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
Treatment: Hepatitis C

Zerbaxa
Ceftolozane/Tazobactam

PatentsExpiration Date
US7129232May 15, 2028
US8685957September 27, 2032
US8476425September 27, 2032
US8906898May 28, 2034

Dosage: Intravenous
Company: Merck & Co
Ingredients: CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM
Treatment: Urinary Tract Infections

Kybella
Deoxycholic Acid

PatentsExpiration Date
US8242294May 16, 2028

Dosage: Injections
Company: Kythera Biopharmaceuticals Inc
Ingredients: DEOXYCHOLIC ACID
Treatment: Double Chin

Tepmetko
Tepotinib

PatentsExpiration Date
US8921357May 30, 2028
US8329692October 30, 2029
US8580781March 19, 2030

Dosage: Oral
Company: Emd Serono Inc
Ingredients: TEPOTINIB HYDROCHLORIDE
Treatment: Non-small Cell Lung Cancer (NSCLC)

Kisqali
Ribociclib

PatentsExpiration Date
US8324225June 17, 2028
US8415355August 21, 2029
US8685980May 25, 2030
US9193732November 9, 2031

Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: RIBOCICLIB SUCCINATE
Treatment: Breast Cancer

Osmoprep
Sodium Phosphate Monobasic Monohydrate And Sodium Phosphate Dibasic Anhydrous

PatentsExpiration Date
US7687075June 22, 2028

Dosage: Oral
Company: Salix Pharmaceuticals Inc
Ingredients: SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
Treatment: Constipation

Rozlytrek
Entrectinib

PatentsExpiration Date
US9029356July 8, 2028
US8299057March 1, 2029
US9085565May 22, 2033
US10738037May 18, 2037

Dosage: Oral
Company: Genentech Inc
Ingredients: ENTRECTINIB
Treatment: Non-small Cell Lung Cancer

Minivelle
Estradiol

PatentsExpiration Date
US9724310July 10, 2028
US8231906July 4, 2030

Dosage: Transdermal
Company: Noven Pharmaceuticals Inc
Ingredients: ESTRADIOL
Treatment: Menopause

Truseltiq
Infigratinib

PatentsExpiration Date
US9067896August 6, 2028
US8552002August 25, 2029

Dosage: Oral
Company: Helsinn Healthcare Sa
Ingredients: INFIGRATINIB PHOSPHATE
Treatment: Cholangiocarcinoma

Syndros
Dronabinol

PatentsExpiration Date
US9345771August 6, 2028
US8222292August 6, 2028
US10265293August 6, 2028
US11253472August 6, 2028

Dosage: Oral
Company: Benuvia Therapeutics Inc
Ingredients: DRONABINOL
Treatment: Nausea And Vomiting Caused By Chemotherapy

Vizimpro
Dacomitinib

PatentsExpiration Date
US7772243August 26, 2028

Dosage: Oral
Company: Pfizer Inc
Ingredients: DACOMITINIB
Treatment: Non-small Cell Lung Cancer (NSCLC)

Viekira Pak
Ombitasvir/Paritaprevir/Ritonavir

PatentsExpiration Date
US8501238September 17, 2028
US8188104May 17, 2029
US8642538September 10, 2029
US8420596April 10, 2031
US8691938April 13, 2032

Dosage: Oral
Company: Abbvie Inc
Ingredients: DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
Treatment: Hepatitis C

Epclusa
Sofosbuvir/Velpatasvir

PatentsExpiration Date
US8580765September 21, 2028
US8334270September 21, 2028
US9085573September 21, 2028
US7964580September 26, 2029
US8633309September 26, 2029
US9284342March 13, 2031
US8618076June 11, 2031
US8575135May 16, 2033
US8921341May 16, 2033
US8940718May 16, 2033

Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: SOFOSBUVIR; VELPATASVIR
Treatment: Hepatitis C

Inqovi
Decitabine/Cedazuridine

PatentsExpiration Date
US9567363October 16, 2028
US8268800August 22, 2030

Dosage: Oral
Company: Otsuka Pharmaceutical Co Ltd
Ingredients: CEDAZURIDINE; DECITABINE
Treatment: Myelodysplastic Syndromes (MDS) And Chronic Myelomonocytic Leukemia (CMML)

Erivedge
Vismodegib

PatentsExpiration Date
US7888364November 11, 2028

Dosage: Oral
Company: Genentech Inc
Ingredients: VISMODEGIB
Treatment: Basal-cell Carcinoma (BCC)

Zemdri
Plazomicin

PatentsExpiration Date
US9688711November 21, 2028
US8383596June 2, 2031

Dosage: Intravenous
Company: Cipla USA Inc
Ingredients: PLAZOMICIN SULFATE
Treatment: Urinary Tract Infections

Remodulin
Treprostinil

PatentsExpiration Date
US9604901December 15, 2028
US9593066December 15, 2028

Dosage: Intravenous, Subcutaneous
Company: United Therapeutics Corp
Ingredients: TREPROSTINIL
Treatment: Pulmonary Arterial Hypertension

Vraylar
Cariprazine

PatentsExpiration Date
US7943621December 16, 2028
US7737142September 17, 2029

Dosage: Oral
Company: Allergan
Ingredients: CARIPRAZINE HYDROCHLORIDE
Treatment: Schizophrenia, Bipolar Mania, and Bipolar Depression

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.